1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
BARDA Broad Agency Announcement (BAA-23-100-SOL-00004) is sponsored by Biomedical Advanced Research and Development Authority. BARDA seeks to fund the advanced research and development of medical countermeasures for chemical, biological, radiological, and nuclear threats, as well as pandemic influenza and emerging infectious diseases. This includes diagnostic med tech and therapeutic delivery systems.
Get alerted about grants like this
Save a search for “Biomedical Advanced Research and Development Authority” or related topics and get emailed when new opportunities appear.
Search similar grants →According to the current listing, eligibility includes: Small businesses, large businesses, and research institutions. Confirm the full requirements in the official notice before applying.
BARDA Broad Agency Announcement (BAA-23-100-SOL-00004) accepts applications on a rolling basis — there is no single fixed deadline. Check the official notice for any cycle-specific review dates.
BARDA Broad Agency Announcement (BAA-23-100-SOL-00004) is funded by Biomedical Advanced Research and Development Authority. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
BioTools Innovator VANGUARD is the Enabling Technologies hub of the BARDA Accelerator Network supporting startups developing medical countermeasures for biothreats and pandemic preparedness. Funded scope includes AI-enabled biotools across drug discovery (machine learning for target identification, AI-driven small molecule and biologics design), bioanalytic and diagnostic instrumentation (computer vision for pathology, AI-enabled point-of-care diagnostics), and biomanufacturing (process modeling, predictive maintenance). The 2026 Accelerator Track application opens in October 2026; selected companies join a four-month accelerator with technical, regulatory, and commercialization support from BARDA.
BARDA Broad Agency Announcement (BAA) for Medical Countermeasures (MCMs) for CBRN Threats, Pandemic Influenza, and Emerging Infectious Diseases is sponsored by Biomedical Advanced Research and Development Authority (BARDA). BARDA's BAA supports the advanced research and development of medical countermeasures, including those for antimicrobial resistance, to address chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases.
The April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read articleNIH's accelerating use of multiyear-funded grants — 601 awards worth $402 million in the first half of FY26, against just 146 awards worth $75 million in the same window of FY24 — has produced a fiscal contraction at research universities that has begun cascading into PhD admissions. AAU member institutions are admitting smaller graduate cohorts than they did in 2024 or 2025, with downstream consequences for the biomedical workforce, lab continuity, and the foreign-student pipeline through 2030. Why the contraction is structural rather than cyclical, and what universities, PIs, and prospective trainees should be doing in the second half of 2026.
Read articleARPA-H launched the Intelligent Generator of Research program on May 5, 2026 with only three anticipated OT awards, a Solution Summary deadline of June 25, and a full proposal due August 6. The program is also piloting LLM-assisted proposal review. Here is the strategic read.
Read article